Pharmaceuticals firm Alkem Laboratories declares Q4FY22 result: Key highlights of Q4FY22 financial performance: Total Revenue from Operations was Rs 24,839 million, YoY growth of 13.3%. India sales were Rs 17,187 million, YoY growth of 16.7% International sales were Rs 7,411 million, YoY growth of 7.3% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 3,372 million, resulting in EBITDA margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY R&D; expenses for the quarter was Rs 1,634 million, or 6.6% of total revenue from operations compared to Rs 1,408 million in Q4FY21 at 6.4% of total revenue from operations Profit before tax (PBT) was Rs 2,427 million, a decline of 6.0% compared to Q4FY21. Exceptional Item of Rs 150 million debit was on account of fair value of an investment Net Profit (after Minority Interest) was Rs 1,076 million, YoY decline of 55.2%. Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "FY22 was a mixed bag for the Company as our India business did well helped by COVID-19 tailwinds, while our US business faced significant pricing pressure. We forayed in the Indian respiratory segment with the launch of Pulmocare division which received an encouraging response. Our biotech subsidiary Enzene also made good progress with product launches in India and signing multiple product out-licensing deals. Going forward, while we are positive about our growth prospects given the levers we have built over the years, navigating the inflationary pressures of high raw material prices and increased freight rates, would be a key challenge for the Company." Result PDF
Conference Call with Alkem Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Alkem Laboratories Ltd. Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.